Enhancing Candida auris Surveillance in High-Risk Settings by Implementing a High-Throughput Molecular Assay on the Hologic Fusion Open Access Platform
-
Published:2024-04-12
Issue:4
Volume:10
Page:285
-
ISSN:2309-608X
-
Container-title:Journal of Fungi
-
language:en
-
Short-container-title:JoF
Author:
Cerqueira Filipe M.1, Bertsch Jennifer1, DeMaet Mary Ann1, York Teresa1, McDougal April1ORCID, Patel Janak A.1ORCID, Ren Ping1ORCID
Affiliation:
1. Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA
Abstract
Candida auris, a resilient pathogenic yeast with frequent multidrug resistance, presents a persistent challenge in healthcare settings. The timely identification of C. auris is crucial for infection control and prevention, especially in facilities facing unique hurdles, such as our institution, which serves four major hospitals and approximately 80% of the Texas inmate population. Understaffing, communal living, and financial constraints exacerbate infection control issues. To address common staff shortages, streamline testing services, and enhance testing efficiency, there was a pressing need for rapid and high-throughput detection of C. auris. This study presents the validation and utility of an assay implemented on the Hologic Fusion Open Access platform using samples collected from high-risk patients’ axilla and groin areas, as well as environmental swab samples from patient rooms. Our assay complemented efforts to control C. auris outbreaks within our healthcare system, providing valuable insights into its presence within surveillance samples. This assay demonstrated the value of high-throughput molecular detection platforms in challenging healthcare environments by aiding infection preventionists in containing the spread of C. auris and preventing nosocomial infections. Our research contributes essential data on the suitability and performance of the Hologic Fusion Open Access platform for C. auris detection. These findings hold significant implications for enhancing surveillance and control measures in high-risk settings, making a significant impact on the field of infection control and prevention.
Reference32 articles.
1. Cristina, M.L., Spagnolo, A.M., Sartini, M., Carbone, A., Oliva, M., Schinca, E., Boni, S., and Pontali, E. (2023). An Overview on Candida auris in Healthcare Settings. J. Fungi, 9. 2. First three reported cases of nosocomial fungemia caused by Candida auris;Lee;J. Clin. Microbiol.,2011 3. Du, H., Bing, J., Hu, T., Ennis, C.L., Nobile, C.J., and Huang, G. (2020). Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog., 16. 4. Sabino, R., Veríssimo, C., Pereira, Á.A., and Antunes, F. (2020). Candida auris, an Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind?. Microorganisms, 8. 5. Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents;Jacobs;Antimicrob. Agents Chemother.,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|